menu
Over 180 companies from different regions across the globe presently claim to provide services{RootsAnalysis}
Over 180 companies from different regions across the globe presently claim to provide services{RootsAnalysis}
Over 180 companies from different regions across the globe presently claim to provide services{RootsAnalysis}

Over 180 companies from different regions across the globe presently claim to provide services{RootsAnalysis}

It is estimated thataround 80% of innovator companies rely on external companion diagnosticdevelopers, mostly owing to the lack of the required in-house expertise. On theother hand, there are numerous contract service providers, offering vastportfolios of services for diagnostic test / assay development. Such companiesare known to possess extensive technical knowledge, and experience in workingwith cutting-edge analytical tools and technologies, such as in situhybridization (ISH), immunohistochemistry (IHC), next generation sequencing(NGS), polymerase chain reaction (PCR).

 

To  order this 320+ page report, which features120+ figures and 115+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

The USD 800+ million (by 2030) financialopportunity within the companion diagnostics development services market hasbeen analysed across the following segments:

§ Type of ServiceOffered

  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation

 

§ Type of AssayTechnique Used

§ in situ hybridization/ Immunohistochemistry

§ Next GenerationSequencing

§ Polymerase ChainReaction

§ Others

 

§ Key geographicalregions

§  North America

§  Europe

§  Asia Pacific

 

 

Thereport features inputs from eminent industry stakeholders, according to whom thedevelopment of companion diagnostics is largely outsourced, owing to the exorbitantcosts associated with the setting-up of in-house expertise / capabilities. Thereport includes detailed transcripts of discussions held with the followingexperts:

§ Anton Iliuk (Presidentand Chief Technology Officer, Tymora Analytica)

§ Paul Kortschak(Senior Vice President, Novodiax)

§ Pablo Ortiz (ChiefExecutive officer, OWL Metabolomics)

§ Lawrence M. Weiss(Chief Scientific Officer, NeoGenomics Laboratories)

 

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Landscape

5. Company Profiles

 

6. Partnerships and Collaborations

7. Likely Partner Analysis

8. Company Competitiveness Analysis

9. Stakeholder Needs Analysis

10. Value Chain Analysis

 

11. Clinical Research on Cancer Biomarkers: BigPharma Perspective

 

12. Market Forecast And Opportunity Analysis

 

13. Executive Insights

 

14. Appendix 1: Tabulated Data

 

15. Appendix 2: List of Companies andOrganizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com